VX-702

TargetMol
Product Code: TAR-T2513
Supplier: TargetMol
CodeSizePrice
TAR-T2513-1mL1 mL * 10 mM (in DMSO)£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2513-10mg10mg£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2513-25mg25mg£132.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2513-50mg50mg£179.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
VX-702 is a highly specific p38α MAPK inhibitor, 14-fold higher selectivity for the p38α than p38β. VX-702 is a small molecule investigational oral anti-cytokine therapy for treatment of inflammatory diseases, specifically rheumatoid arthritis (RA).
CAS:
745833-23-2
Formula:
C19H12F4N4O2
Molecular Weight:
404.325
Pathway:
MAPK; Autophagy
Purity:
0.99
SMILES:
NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F
Target:
p38 MAPK; Autophagy

References

1. Kuliopulos A, et al. Thromb Haemost, 2004, 92(6), 1387-1393. 2. Braddock M, IDDB Meeting Report, 2005, March 14-15. 3. Gill A, IDDB Meeing Report, 2002, March 06-08. 4. Bhattacharya K, et al. Circulation, 2003, 108(17), 882.